Loading...
XNAS
AUPH
Market cap2.06bUSD
Jun 05, Last price  
15.84USD
1D
-3.24%
1Q
10.61%
Jan 2017
654.29%
IPO
296.00%
Name

Aurinia Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:AUPH chart
P/E
354.15
P/S
8.66
EPS
0.04
Div Yield, %
—
Shrs. gr., 5y
9.46%
Rev. gr., 5y
274.78%
Revenues
235m
+33.97%
1,177,8883,522,6492,334,6463,876,7464,052,1443,420,452927,5226,157,836948,561278,000235,000173,000420,000463,000318,00050,118,00045,605,000134,030,000175,513,000235,133,000
Net income
6m
P
000000000-16,647,000-18,607,000-23,295,000-70,792,000-64,120,000-123,846,000-102,680,000-180,966,000-108,180,000-78,020,0005,752,000
CFO
44m
P
000000000-16,904,000-17,766,000-18,713,000-41,169,000-51,610,000-63,456,000-69,858,000-157,692,000-79,529,000-33,461,00044,388,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. The company is headquartered in Victoria, Canada.
URL
https://www.auriniapharma.com
IPO date
Jul 16, 2001
Employees
300
Domiciled in
CA
Incorporated in
CA

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT